ONCE-DAILY INHALED UMECLIDINIUM/VILANTEROL COMBINATION THERAPY COMPARED WITH PLACEBO ON EXACERBATIONS IN CHINESE PATIENTS WITH COPD

被引：0
|
作者：
Zheng, Jinping [1 ]
Goh, Aik [2 ]
Huang, Chunchen [2 ]
Luo, Xian [2 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China
[2] GlaxoSmithKline, Shanghai, Peoples R China
来源：
RESPIROLOGY | 2017年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AO110
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [41] Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
    Albertson, Timothy E.
    Bowman, Willis S.
    Harper, Richart W.
    Godbout, Regina M.
    Murin, Susan
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 : 1251 - 1265
  • [42] Clinical Usefulness of Once-Daily Triple Therapy, Ciclesonide and Tiotropium Bromide/Olodaterol Combination Inhaler for COPD Patients
    Masayuki, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [43] Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
    François Maltais
    Leif Bjermer
    Edward M. Kerwin
    Paul W. Jones
    Michael L. Watkins
    Lee Tombs
    Ian P. Naya
    Isabelle H. Boucot
    David A. Lipson
    Chris Compton
    Mitra Vahdati-Bolouri
    Claus F. Vogelmeier
    Respiratory Research, 20
  • [44] Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
    Maltais, Francois
    Bjermer, Leif
    Kerwin, Edward M.
    Jones, Paul W.
    Watkins, Michael L.
    Tombs, Lee
    Naya, Ian P.
    Boucot, Isabelle H.
    Lipson, David A.
    Compton, Chris
    Vahdati-Bolouri, Mitra
    Vogelmeier, Claus F.
    RESPIRATORY RESEARCH, 2019, 20 (01) : 238
  • [45] Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials (vol 1, pg 210, 2013)
    Dransfield, M. T.
    Bourbeau, J.
    Jones, P. W.
    LANCET RESPIRATORY MEDICINE, 2013, 1 (03): : 186 - 186
  • [46] Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study
    Nakamura, Yoichi
    Hozawa, Soichiro
    Sagara, Hironori
    Ohbayashi, Hiroyuki
    Lee, Laurie A.
    Crawford, Jodie
    Tamaoki, Jun
    Nishi, Takanobu
    Fowler, Andrew
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (09) : 1657 - 1665
  • [47] Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data
    Maleki-Yazdi, M. Reza
    Singh, Dave
    Anzueto, Antonio
    Tombs, Lee
    Naya, Ian
    Harris, Stephanie
    Iqbal, Ahmar
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [48] Comparison of COPD Exacerbations With Once-Daily QVA149 Versus Twice-Daily Salmeterol/Fluticasone Combination: The ILLUMINATE Study
    Bateman, Eric
    Vogelmeier, Claus
    Chen, Hungta
    Banerji, Donald
    CHEST, 2014, 145 (03)
  • [49] COMPARISON OF COPD EXACERBATIONS WITH ONCE-DAILY QVA149 VERSUS TWICE-DAILY SALMETEROL/FLUTICASONE COMBINATION: THE ILLUMINATE STUDY
    Vogelmeier, C.
    Bateman, E. D.
    Chen, H.
    Banerji, D.
    THORAX, 2013, 68 : A184 - A185
  • [50] Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy
    Stynes, Gillian
    Svedsater, Henrik
    Wex, Jaro
    Lettis, Sally
    Leather, David
    Castelnuovo, Emanuela
    Detry, Michelle
    Berry, Scott
    RESPIRATORY RESEARCH, 2015, 16
12345